Letter to Editor

Left Bundle Branch Optimized Implantable Cardioverter Defibrillator (LOT-ICD) Implantation in a Patient with Myotonic Dystrophy

Süleyman Cihan Kara¹, Mert Dogan¹, Uğur Canpolat¹

¹ Department of Cardiology, Hacettepe University, Faculty of Medicine, Ankara, Türkiye

Received: 2024-01-30

Accepted: 2024-02-25

Published Online: 2024-02-29

Correspondence

Ugur Canpolat, MD, Address: Hacettepe University, Faculty of Medicine, Department of Cardiology, 06100, Altindag, Ankara, Türkiye E-mail: dru_canpolat@yahoo.com

© 2024, European Journal of Therapeutics, Gaziantep University School of Medicine.

3 1 2

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Letter to Editor,

Abstract

Left bundle branch (LBB) optimized implantable cardioverter defibrillator (LOT-ICD) is a recently emerged alternative to the standard biventricular pacing - ICD (BiVp-ICD). The IS-1 connector pin of the ICD lead was closed with a protective cap and the LBB pacing (LBBP) lead was inserted into the ICD generator at the ventricular P/S hole. Herein, we presented a myotonic dystrophy patient who underwent LOT-ICD device implantation because of a high degree of atrioventricular block and heart failure with mid-range ejection fraction. A DDD-ICD (DF-1) was implanted in our patient which has been attached to the atrial lead (RA hole), the LBBP lead (ventricular IS-1 hole), and the ICD lead (ventricular DF-1 hole). The IS-1 pin of the ICD lead was closed accordingly. The LOT-ICD should be considered an option to standard BiVp-ICD associated with lower cost, lower procedure time, and no phrenic nerve capture.


Keywords: Implantable cardioverter defibrillator, left bundle branch pacing

Patients with myotonic dystrophy type 1 (MD1) have an increased risk of sudden cardiac death because of cardiac involvement and conduction abnormalities [1, 2]. Permanent pacemaker implantation is recommended in MD1 patients with advanced atrioventricular block (AVB) independent of the symptoms [3]. Cardiac resynchronization therapy (CRT) may be considered in DM1 patients who have permanent pacemaker dependency and left ventricular ejection fraction (LVEF) of <50% [4]. Although overt myocardial involvement in DM1 is infrequent, CRT implantation in DM1 patients was also reported previously [5-7].


Left bundle branch pacing (LBBP) is emerged as an alternative pacing method to biventricular CRT [8, 9]. The LBBP is achieved by inserting an electrode into the interventricular septum [10]. Several recent studies implicated that, LBBP is a more effective method and could be an alternative to biventricular CRT [11, 12]. Furthermore, in a recent research, another novel method was emerged and implemented as LBB optimized implantable cardioverter defibrillator (LOT-ICD) due to its high cost of biventricular CRT-D (IS-1 pin of the ventricular lead was closed with a protective cap and LBBP electrode was inserted into ventricular-P/S hole of ICD generator). This method had a lower cost and showed stable lead parameters. Herein, we presented a myotonic dystrophy patient with heart failure with mid-range ejection fraction (HFmrEF) and advanced atrioventricular block (AVB) in whom the LOT-ICD method was used.

A written and verbal informed consent was taken from the patient for submission of this paper. We did not use artificial intelligence (AI)- assisted technologies in the production of submitted work. A 51-year-old female patient with the diagnosis of MD1 and HFmrEF has been hospitalized for a rehabilitation program and consulted us for symptomatic bradycardia (dizziness and pre-syncope). She was under treatment of metoprolol 50 mg/ day, Ramipril 2,5 mg/day, and spironolactone 25 mg/day for HFmrEF. She had no known history of coronary artery disease and her coronary angiography which was performed 7 years ago was normal. Cardiac magnetic resonance imaging (MRI) at the time of HFmrEF revealed no septal scar and LVEF of 41%. Her electrocardiography (ECG) showed sinus rhythm (40 bpm) and a trifascicular block (right bundle branch block, alternating left anterior/posterior hemi block, and first-degree AV block with PR interval of 400 ms) (Figure 1A). Furthermore, another ECG showed a second-degree Mobitz type 2 AVB and ventricular rate of 35 bpm (Figure 1B). Laboratory tests were unremarkable. Transthoracic echocardiography revealed an LVEF of 43% and moderate mitral and tricuspid regurgitation. Metoprolol treatment was stopped. As the patient was symptomatic, a temporary transvenous pacemaker was implanted to bridge the waiting period for metoprolol clearance (Figure 2). However, no improvement in the patient's rhythm was observed, and recurrent non-sustained ventricular tachycardia (NSVT) episodes were documented on telemetry recordings. As the patient would be pacemaker dependent and the LVEF was between 36-50%, we planned to implant a dual-chamber LOT-ICD device functioning as a CRT-D. Under local anesthesia and sedation, a left axillary vein puncture was performed. DF-1 ICD lead was placed into the right ventricle apex. Then, Solia S60 ventricular lead was inserted deep into the mid-interventricular septum with the support of Selectra 3D 55-39 (Biotronik, Berlin, Germany) delivery sheath and unipolar pacing parameters were compatible with the nonselective LBBP (V6 R wave peak time of 72 ms and V6-V1 inter-peak delay 40 ms, and a QRS transition during threshold test) (Supplementary Video 1). Pacing parameters of unipolar and bipolar pacing threshold/impedances were 0.6 and 0.7 V (a)0.4 ms / 615 and 773 ohms, R wave sense amplitude: 8.6 mV. Thereafter, atrial lead was placed into the right atrial appendage. After slitting the delivery sheath and fixation of the leads to the muscular tissue with the sleeves, the atrial lead pin was inserted into the RA hole, the defibrillation lead pin was inserted into the ventricular DF-1 hole, and the LBBP lead was inserted into the ventricular IS-1 port of the DDD-ICD (DF-1) pulse generator. IS-1 pin of the ventricular lead was closed with a protective

cap and had left freely (Figure 3A & B). Post-procedural ECG showed a paced QRS duration of 120 ms with bipolar pacing of the device (Figure 4). No periprocedural complication was observed and the remaining hospitalization was uneventful. Beta-blocker treatment was re-initiated accordingly. The patient was asymptomatic and the pacemaker parameters were normal in the 1st and 3rd follow-up visits.



Supplementary Video 1. Contrast injection via delivery sheath showed the depth of the left bundle branch pacing lead in the septum. (Available at <u>https://eurjther.com/index.php/home/article/view/2038/1546</u>)



European Journal of Therapeutics (2024)

Figure 1. A. Electrocardiography showed sinus rhythm (40 bpm) and a trifascicular block (right bundle branch block, alternating left anterior/posterior hemi-block, and first-degree AV block with PR interval of 400 ms). **B.** Follow-up electrocardiography showed a second-degree Mobitz type 2 AV block and ventricular rate of 35 bpm.




Figure 2. Electrocardiography showed a pacemaker rhythm with a paced QRS duration of 200 ms




Figure 3. A. The fluoroscopy at the left anterior oblique view shows the localizations of the LOT-ICD device leads. **B.** The connections of the LOT-ICD device lead to the pulse generator.



Figure 4. Post-procedural electrocardiography showed a paced QRS duration of 120 ms with bipolar pacing of the LOT-ICD device and terminal small r wave in V1 derivation.

In the current paper, we presented a female patient with MD1 and HFmrEF who consulted us for symptomatic bradycardia in whom a dual-chamber LOT-ICD device was implanted. MD1 is an autosomal dominant neuromuscular disorder characterized by multi-systemic involvement including the heart. It has been reported that sudden cardiac death can occur in MD1 patients because of myocardial and conduction system involvement [1, 2]. Overt myocardial involvement was rarely reported [5-7]. Although there were various data about conduction system abnormalities and permanent pacemaker implantation [1, 3], the data about biventricular CRT implantation in MD1 patients was scarce [5-7]. Furthermore, there is no clear consensus about biventricular CRT or ICD implantation in MD1. Groh et al. [1] reported the presence of atrial tachyarrhythmia, a PR interval > 240 milliseconds, aberrant QRS conduction, and advanced AV block as significant predictors of sudden death. In a recent study, Benhayon et al. [13] showed that the presence of AV conduction abnormalities in MD1 patients was also associated with an increased risk for ventricular tachyarrhythmia. Their study also revealed that one-third of the MD patients who received a primary prevention ICD experienced ventricular arrhythmia during a 22-month follow-up. Thus, it has been suggested that there is a role for CRT-ICD in DM1 patients who require permanent pacemaker implantation based on the progressive nature of the cardiac involvement [14]. Following the previous literature, our patient experienced multiple NSVT episodes with the risk factors for ventricular tachyarrhythmia and sudden cardiac death such as an advanced AV block, aberrant QRS conduction, and mid-range myocardial involvement. Thus, we implanted a pacemaker with a defibrillator function.

LBBP has emerged and is adopted very fast in clinical practice [10]. It has better LV synchronization and acute hemodynamic response compared to biventricular CRT [15]. Recent studies showed that CRT via LBBP was more effective than biventricular CRT [11, 12]. Interventricular septal scar and severe His-Purkinje conduction abnormality were prognostic factors for ineffective LBBP alone, and cMRI-guided LBBP might be a better option to be successful [16, 17]. LOT-CRT or HOT-CRT are better options in case of extensive septal scar or severe His-Purkinje conduction abnormality. LOT-ICD is a recently emerged cost-effective resynchronization technique. DDD-ICD generator ventricular P/S hole is occupied by LBBP lead, and the IS-1 pin of ICD lead is closed with a protective cap. It is shown that the LOT-ICD is associated with stable R wave sensing in arrhythmia detection, low cost, and low procedure time that cause lower radiation dose.

Furthermore, the LOT-ICD resulted in significant improvement of LVEF, LV end-diastolic diameter, and QRS durations of the patients [18]. It also overcomes the limitations of biventricular CRT implantation such as coronary sinus lead dislodgement, absence of appropriate coronary sinus branch, non-response to biventricular CRT, and phrenic nerve capture [19]. The main reason for using a LOT-ICD device rather than a biventricular CRT device is its lower cost of the pulse generator. Ponnusamy et al. [18] reported a 30% reduction in the cost of the therapy without any obstacle in clinical response with the LOT-ICD device. This novel cost-effective resynchronization method can be preferred in developing or under-developed countries with limited health sources and no reimbursement for device therapies [20]. Our MD1 patient had a symptomatic advanced AV block, documented NSVT episodes, and HFmrEF (LVEF 43%). It is recommended to perform a cardiac physiological pacing (LBBP or His bundle pacing) or biventricular CRT in such a patient who requires substantial ventricular pacing, NSVT episodes, and LVEF of 36-50%. The presence of myocardial involvement and an advanced AV block were thought as significant risk factors for sudden death in our patient. Thus, we prefer to perform LOT-ICD functioning as a CRT-D.

In conclusion, LOT-ICD is a promising alternative to biventricular CRT-D that has lower cost and mostly better pacing and procedure-related properties. Future large-scale randomized studies comparing LOT-ICD with biventricular BiVp-ICD are needed.

Funding: None.

Conflict of interest: U.C.: Proctoring for Biotronik & Medtronic; S.C.K. and M.D.: None declared.

REFERENCES

- [1] Groh WJ, Groh MR, Saha C, Kincaid JC, Simmons Z, Ciafaloni E, Pourmand R, Otten RF, Bhakta D, Nair GV, Marashdeh MM, Zipes DP, Pascuzzi RM (2008) Electrocardiographic abnormalities and sudden death in myotonic dystrophy type 1. N Engl J Med 358:2688-2697. https://doi.org/10.1056/NEJMoa062800
- [2] Russo V, Capolongo A, Bottino R, Carbone A, Palladino A, Liccardo B, Nigro G, Marchel M, Golino P, D'Andrea A (2023) Echocardiographic Features of Cardiac Involvement

in Myotonic Dystrophy 1: Prevalence and Prognostic Value. J Clin Med 12. <u>https://doi.org/10.3390/jcm12051947</u>

- [3] Glikson M, Nielsen JC, Kronborg MB, Michowitz Y, Auricchio A, Barbash IM, Barrabes JA, Boriani G, Braunschweig F, Brignole M, Burri H, Coats AJS, Deharo JC, Delgado V, Diller GP, Israel CW, Keren A, Knops RE, Kotecha D, Leclercq C, Merkely B, Starck C, Thylen I, Tolosana JM, Group ESCSD (2021) 2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy. Eur Heart J 42:3427-3520. <u>https://doi.org/10.1093/</u> <u>eurheartij/ehab364</u>
- Chung MK, Patton KK, Lau CP, Dal Forno ARJ, Al-Khatib [4] SM, Arora V, Birgersdotter-Green UM, Cha YM, Chung EH, Cronin EM, Curtis AB, Cygankiewicz I, Dandamudi G, Dubin AM, Ensch DP, Glotzer TV, Gold MR, Goldberger ZD, Gopinathannair R, Gorodeski EZ, Gutierrez A, Guzman JC, Huang W, Imrey PB, Indik JH, Karim S, Karpawich PP, Khaykin Y, Kiehl EL, Kron J, Kutyifa V, Link MS, Marine JE, Mullens W, Park SJ, Parkash R, Patete MF, Pathak RK, Perona CA, Rickard J, Schoenfeld MH, Seow SC, Shen WK, Shoda M, Singh JP, Slotwiner DJ, Sridhar ARM, Srivatsa UN, Stecker EC, Tanawuttiwat T, Tang WHW, Tapias CA, Tracy CM, Upadhyay GA, Varma N, Vernooy K, Vijayaraman P, Worsnick SA, Zareba W, Zeitler EP (2023) 2023 HRS/APHRS/LAHRS guideline on cardiac physiologic pacing for the avoidance and mitigation of heart failure. Heart Rhythm 20:e17-e91. https://doi.org/10.1016/j. hrthm.2023.03.1538
- [5] Russo V, Rago A, Antonio Papa A, Nigro G (2012) Cardiac resynchronization improves heart failure in one patient with myotonic dystrophy type 1. A case report. Acta Myol 31:154-155.
- [6] Russo V, Rago A, D'Andrea A, Politano L, Nigro G (2012) Early onset "electrical" heart failure in myotonic dystrophy type 1 patient: the role of ICD biventricular pacing. Anadolu Kardiyol Derg 12:517-519. <u>https://doi.org/10.5152/ akd.2012.161</u>
- [7] Kilic T, Vural A, Ural D, Sahin T, Agacdiken A, Ertas G, Yildiz Y, Komsuoglu B (2007) Cardiac resynchronization therapy in a case of myotonic dystrophy (Steinert's disease) and dilated cardiomyopathy. Pacing Clin Electrophysiol 30:916-920. <u>https://doi.org/10.1111/j.1540-8159.2007.00782.x</u>

- [8] Huang W, Wu S, Vijayaraman P, Su L, Chen X, Cai B, Zou J, Lan R, Fu G, Mao G, Ellenbogen KA, Whinnett ZI, Tung R (2020) Cardiac Resynchronization Therapy in Patients With Nonischemic Cardiomyopathy Using Left Bundle Branch Pacing. JACC Clin Electrophysiol 6:849-858. <u>https://doi.org/10.1016/j.jacep.2020.04.011</u>
- [9] Vijayaraman P, Ponnusamy S, Cano O, Sharma PS, Naperkowski A, Subsposh FA, Moskal P, Bednarek A, Dal Forno AR, Young W, Nanda S, Beer D, Herweg B, Jastrzebski M (2021) Left Bundle Branch Area Pacing for Cardiac Resynchronization Therapy: Results From the International LBBAP Collaborative Study Group. JACC Clin Electrophysiol 7:135-147. <u>https://doi.org/10.1016/j. jacep.2020.08.015</u>
- [10] Burri H, Jastrzebski M, Cano O, Curila K, de Pooter J, Huang W, Israel C, Joza J, Romero J, Vernooy K, Vijayaraman P, Whinnett Z, Zanon F (2023) EHRA clinical consensus statement on conduction system pacing implantation: endorsed by the Asia Pacific Heart Rhythm Society (APHRS), Canadian Heart Rhythm Society (CHRS), and Latin American Heart Rhythm Society (LAHRS). Europace 25:1208-1236. https://doi.org/10.1093/europace/euad043
- [11] Diaz JC, Sauer WH, Duque M, Koplan BA, Braunstein ED, Marin JE, Aristizabal J, Nino CD, Bastidas O, Martinez JM, Hoyos C, Matos CD, Lopez-Cabanillas N, Steiger NA, Kapur S, Tadros TM, Martin DT, Zei PC, Tedrow UB, Romero JE (2023) Left Bundle Branch Area Pacing Versus Biventricular Pacing as Initial Strategy for Cardiac Resynchronization. JACC Clin Electrophysiol 9:1568-1581. https://doi.org/10.1016/j.jacep.2023.04.015
- [12] Vijayaraman P, Sharma PS, Cano O, Ponnusamy SS, Herweg B, Zanon F, Jastrzebski M, Zou J, Chelu MG, Vernooy K, Whinnett ZI, Nair GM, Molina-Lerma M, Curila K, Zalavadia D, Haseeb A, Dye C, Vipparthy SC, Brunetti R, Moskal P, Ross A, van Stipdonk A, George J, Qadeer YK, Mumtaz M, Kolominsky J, Zahra SA, Golian M, Marcantoni L, Subzposh FA, Ellenbogen KA (2023) Comparison of Left Bundle Branch Area Pacing and Biventricular Pacing in Candidates for Resynchronization Therapy. J Am Coll Cardiol 82:228-241. <u>https://doi. org/10.1016/j.jacc.2023.05.006</u>
- [13] Benhayon D, Lugo R, Patel R, Carballeira L, Elman L, Cooper JM (2015) Long-term arrhythmia follow-up of patients with

myotonic dystrophy. J Cardiovasc Electrophysiol 26:305-310. https://doi.org/10.1111/jce.12604

- [14] Said SA, Baart JC, de Voogt WG (2006) Pacing for conduction disturbances in Steinert's disease: a new indication for biventricular ICD? Neth Heart J 14:258-262.
- [15] Ali N, Arnold AD, Miyazawa AA, Keene D, Chow JJ, Little I, Peters NS, Kanagaratnam P, Qureshi N, Ng FS, Linton NWF, Lefroy DC, Francis DP, Phang Boon L, Tanner MA, Muthumala A, Shun-Shin MJ, Cole GD, Whinnett ZI (2023) Comparison of methods for delivering cardiac resynchronization therapy: an acute electrical and haemodynamic within-patient comparison of left bundle branch area, His bundle, and biventricular pacing. Europace 25:1060-1067. <u>https://doi.org/10.1093/europace/euac245</u>
- [16] Strocchi M, Gillette K, Neic A, Elliott MK, Wijesuriya N, Mehta V, Vigmond EJ, Plank G, Rinaldi CA, Niederer SA (2023) Effect of scar and His-Purkinje and myocardium conduction on response to conduction system pacing. J Cardiovasc Electrophysiol 34:984-993. <u>https://doi. org/10.1111/jce.15847</u>
- [17] Ponnusamy SS, Ganesan V, Ramalingam V, Syed T, Mariappan S, Murugan S, Kumar M, Anand V, Murugan M, Vijayaraman P (2023) MAgnetic resonance imaging based DUal lead cardiac Resynchronization therapy: A prospectIve Left Bundle Branch Pacing study (MADURAI LBBP study). Heart Rhythm 20:1119-1127. <u>https://doi. org/10.1016/j.hrthm.2023.05.019</u>
- [18] Ponnusamy SS, Ramalingam V, Ganesan V, Syed T, Kumar M, Mariappan S, Murugan S, Basil W, Vijayaraman P (2022) Left bundle branch pacing-optimized implantable cardioverter-defibrillator (LOT-ICD) for cardiac resynchronization therapy: A pilot study. Heart Rhythm O2 3:723-727. https://doi.org/10.1016/j.hroo.2022.08.004
- [19] van Rees JB, de Bie MK, Thijssen J, Borleffs CJ, Schalij MJ, van Erven L (2011) Implantation-related complications of implantable cardioverter-defibrillators and cardiac resynchronization therapy devices: a systematic review of randomized clinical trials. J Am Coll Cardiol 58:995-1000. https://doi.org/10.1016/j.jacc.2011.06.007
- [20] Naik A, Singh B, Yadav R, Pandurangi U, Kler TS, Shankar B, Radhakrishnan R, Rajan V, Bhatia V, Kaul U, Varma J, Dora S, Narasimhan C (2018) Cardiac resynchronization

therapy is associated with improvement in clinical outcomes in Indian heart failure patients: Results of a large, long-term observational study. Indian Heart J 70 Suppl 3:S377-S383. https://doi.org/10.1016/j.ihj.2018.07.010

How to Cite;

Kara SC, Dogan M, Canpolat U (2024) Left Bundle Branch Optimized Implantable Cardioverter Defibrillator (LOT-ICD) Implantation in a Patient with Myotonic Dystrophy. Eur J Ther. 30(3):362-367. <u>https://doi.org/10.58600/</u> eurjther2038